Ascletis Pharma Company Top Insiders

Ascletis Pharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.053) % which means that it has lost $0.053 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0632) %, meaning that it generated substantial loss on money invested by shareholders. Ascletis Pharma's management efficiency ratios could be used to measure how well Ascletis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Ascletis Pharma holds a total of 1.09 Billion outstanding shares. Ascletis Pharma shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 67.02 percent of Ascletis Pharma outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in pink sheets such as Ascletis Pharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Ascletis Pharma, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Ascletis Pharma Workforce Comparison

The company has Profit Margin (PM) of (2.24) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.11.

Ascletis Pharma Benchmark Summation

Ascletis Pharma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Ascletis Pharma often depends on how effective the management is. Ascletis Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ascletis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ascletis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

When running Ascletis Pharma's price analysis, check to measure Ascletis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascletis Pharma is operating at the current time. Most of Ascletis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascletis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascletis Pharma's price. Additionally, you may evaluate how the addition of Ascletis Pharma to your portfolios can decrease your overall portfolio volatility.